Professional services company Jacobs (NYSE:J) said on Thursday that it has been appointed by French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) as the engineering, procurement and construction management (EPCM) partner for a new insulin manufacturing facility in Frankfurt, Germany, aimed at modernising production and strengthening supply reliability.
Located alongside Sanofi's existing insulin manufacturing campus, the facility will support the production of multiple insulin products and incorporate advanced manufacturing technologies.
Jacobs will provide integrated EPCM services covering design, procurement, construction management and commissioning, deploying multidisciplinary teams to oversee the project through startup. The development will leverage existing site infrastructure and advanced manufacturing systems to support efficient operations.
Ocular Therapeutix reports inducement equity awards granted to nine new employees
Foventa makes key CMO and CFO appointments
BioCare climbs 1,145 places on Inc. 5000 list
DuPont recognised with R&D 100 Award for innovation in healthcare
Synaptiq Therapeutics launches and acquires clinical-stage SYN-001 programme
WuXi AppTec named to FTSE4Good Index Series for fourth consecutive year
Kibow Biotech receives AANP Corporation of the Year Award
EDX Medical to provide molecular profiling services to Astron Health
Futura Medical appoints Market Performance Group as new US distribution partner for Eroxon
MaaT Pharma to seek review after CHMP negative opinion on MaaT013 application
Sensei Biotherapeutics changes name to Faeth Therapeutics
Datavault AI and Wellgistics Health plan DelivMeds AI healthcare venture
Intensity Therapeutics receives Cancer Treatment Technology Innovator of the Year award
Solvonis Therapeutics appoints Water Tower Research to strengthen US market positioning